Forskolin

製品コードS2449 別名:Coleonol

Forskolin化学構造

分子量(MW):410.5

Forskolin is a ubiquitous activator of eukaryotic adenylyl cyclase (AC) in a wide variety of cell types, commonly used to raise levels of cAMP in the study and research of cell physiology.

サイズ 価格(税別)  
JPY 23240.00
JPY 18260.00
JPY 44820.00
JPY 61420.00
JPY 94620.00

カスタマーフィードバック(2)

  • Eur J Cancer 2014 50(7), 1310-20. Forskolin purchased from Selleck.

    Measurement of cAMP accumulation in INS-1 cells. (A) INS-1, or (B) INS-1 transfected with murine GPR109A for 24 h, or (C) INS-1 transfected with human GPR109A for 24 h were incubated in DMEM (2.5 mM glucose) media with or without PTX (100 ng/ml) for 24 h. Cells were then incubated in KRB supplemented with 2.5 mM glucose, 500 μM IBMX, 10 μM forskolin, and with/without 10 or 100 μM NA for 1 h. After lysis with HCl (0.1 M), cells were sonicated and spun. The supernatants were saved for cAMP measurement by ELISA. (D) Reduction of cAMP accumulation in INS-1 and INS-1 cells transfected with GPR109A in the presence of 10 or 100 μM NA. White bar: INS-1 cells, grey bar: INS-1 cells transfected with murine GPR109A; black bar: INS-1 cells transfected with human GPR109A. (∗ and #p < 0.05, ∗ and ##p < 0.001). (n = 5).

    Gen Comp Endocrinol, 2016, 237:98-108. Forskolin purchased from Selleck.

製品安全説明書

cAMP阻害剤の選択性比較

生物活性

製品説明 Forskolin is a ubiquitous activator of eukaryotic adenylyl cyclase (AC) in a wide variety of cell types, commonly used to raise levels of cAMP in the study and research of cell physiology.
ターゲット
Adenylyl cyclase (AC) [1]
(A wide variety of cell types)
体外試験

Forskolin increases cAMP levels in preparations of membranes, cells, or tissues. Forskolin not only activates AC but also interacts with certain other proteins, including glucose transporters and ion channels. Forskolin is able to promote activation of nine different transmembrane iso-forms of AC, albeit with somewhat less efficacy for AC9, which could be used to provides a means to identify and quantify high-affinity binding sites, i.e., G-proteins (Gs)–AC complexes. Activation of s by GPCRs contributes to Forskolin-stimulated cAMP generation in cells because of s-Forskolin potentiation of AC activity. [1] Forskolin stimulates adenylate cyclase activity without interacting with cell surface receptors. Forskolin's potentiation of cAMP in turn inhibits basophil and mast cell degranulation and histamine release, lowers blood pressure and intraocular pressure, inhibits platelet aggregation, promotes vasodilation, bronchodilation, and thyroid hormone secretion, and stimulates lipolysis in fat cells. Forskolin inhibits the binding of platelet-activating factor (PAF), independently of cAMP formation, which may be a result of Forskolin's direct effect on PAF or via interference with PAF binding to receptor sites. Forskolin also appears to have an effect on several membrane transport proteins, and inhibits glucose transport in erythrocytes, adipocytes, platelets, and other cells. Forskolin is used to treat with glaucoma. [2]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HEK293 MnTxSpVv[3Srb36gRZN{[Xl? MYCxNEDPxE1? NEPXc3g3KGh? NWTtUolGcW6lcnXhd4V{KHCqb4PwbI9zgWyjdHnvckBw\iCxdnXy[ZhxemW|c3XkJGtNUEx|IHH0JHM1OzN? NXjEcFhJOjZ2M{W0PVg>
Mo-DCs NEHlbpNHfW6ldHnvckBCe3OjeR?= MYC1NEDPxE1? NEXxOoQzPOLCiXi= MmX4dJJwdW:2ZYOgTWwuOjNicILv[JVkfGmxbjDpckB1cGVic4Xw[ZJv[XSjboSgc4Yhgnmvb4PhckB{fGmvdXzheIVlKE2xLVTDd:Kh NEXQcoczPjRzMkm0PC=>
RBMECs  NHO1cVlHfW6ldHnvckBCe3OjeR?= MkDaOeKh|ryP MUixxsBp MojmZoxw[2u|IITo[UBT[WNzIHnuZYN1cX[jdHnvckBqdmS3Y3XkJIJ6KEWPQWCtTWk> MkHBNlY{PThyM{m=
INA-6 M4j3[2NmdGxiVnnhZoltcXS7IFHzd4F6 M3\q[|AuOTByIN88US=> MVW3NwKBkWh? MVLpcoR2[2W|IHPlcIwh\GWjdHig[I9{\SCmZYDlcoRmdnSueR?= Mk\lNlY{ODZ4MkS=
OPM-2 MnjWR4VtdCCYaXHibYxqfHliQYPzZZk> NUTtPVhGOC1zMECg{txO NIjuRlU4OuLCiXi= M{DQWIlv\HWlZYOgZ4VtdCCmZXH0bEBld3OnIHTldIVv\GWwdHz5 NUjidJpjOjZ|ME[2NlQ>
U266 NXznPXVFS2WubDDWbYFjcWyrdImgRZN{[Xl? NYnSd2JbOC1zMECg{txO MkPLO|LjiImq NFzMc|VqdmS3Y3XzJINmdGxiZHXheIgh\G:|ZTDk[ZBmdmSnboTsfS=> NXfl[XcxOjZ|ME[2NlQ>
H929 NIHSPINE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NHK4e5AxNTFyMDFOwG0> Ml\TO|LjiImq MmjMbY5lfWOnczDj[YxtKGSnYYToJIRwe2ViZHXw[Y5l\W62bIm= MUCyOlMxPjZ{NB?=
RPMI 8226 NXGxe3pyS2WubDDWbYFjcWyrdImgRZN{[Xl? M1G4TVAuOTByIN88US=> NVW1SIlIPzMkgJno M{O3Oolv\HWlZYOgZ4VtdCCmZXH0bEBld3OnIHTldIVv\GWwdHz5 MYOyOlMxPjZ{NB?=
MDCK  MVHGeY5kfGmxbjDBd5NigQ>? Mlq1NVAhyrWP NUTDeo14OjRiaB?= M1[2R2ROW09? MkjJeZBz\We3bHH0[ZMhfGinIHX4dJJme3Orb36gc4YhXEeILd8yNUBidmRiQ2THSuKh NXL5W3A4OjZ{MEKzOVI>
MDCK  M4HLbGZ2dmO2aX;uJGF{e2G7 NH;0RmkyOCEEtV2= NIC0TJczPCCq NEfVNlZFVVOR MlfnbY5pcWKrdIOgeIhmKGmwY4LlZZNm\CCneIDy[ZN{cW:wIH;mJGZPKGOjdYPl[EBjgSCWR1[t{tIy M3P1eFI3OjB{M{Wy
Spinal cords  NEDD[4VHfW6ldHnvckBCe3OjeR?= NFv1UIMyyqEQvF2= M3rONlMxKG2rbh?= MYrzeIlufWyjdHXzJINCVVBibHX2[Yx{ NID0TYczPjF{NkmyOi=>
BeWo  MWLGeY5kfGmxbjDBd5NigQ>? NIPLbVEzPeLCid88US=> NWLtZ2ZGOjRxNEivO|IhcA>? NIXyVnFt\WGmczD0c{BidiCrbnPy[YF{\SCrbjD0bIUh\XiycnXzd4lwdiCxZjDveIhmeiCodYPpc44hdWG{a3Xydy=> Mn;0NlYxPTN3NEm=
bovine oocytes NYXhdWs4TnWwY4Tpc44hSXO|YYm= NWL4c2tqOTBywrFOwG0> MWqxNuKhcA>? NWjPTINFcW6qaXLpeJMhfGinIHXm[oVkfCCxZjDOVHBCKGGwZD;vdkBPWFCFIITvJJN1cW23bHH0[UBz\XO3bYD0bY9vKG:oIH3lbY9{cXN? NVHWXZNyOjZyNUG2NVE>
Caco-2  NFToPFlHfW6ldHnvckBCe3OjeR?= NELqdZcxNjFxMT:xNEDPxE1? NVrLd45bOjEEoH3pci=> NF\kU4RqdmS3Y3XzJIEh\G:|ZT3k[ZBmdmSnboSgbY5kemWjc3WgbY4hcW62cnHj[YxtfWyjcjDjRW1RKGyndnXsdy=> NFXRZ5IzPjB2OUGwNi=>
Caco-2  NWn4e4poTnWwY4Tpc44hSXO|YYm= NYT6em9WOC5zL{GvNVAh|ryP MWKyOEBp MnnNbY5kemWjc3XzJG1TWDJicILveIVqdiCuZY\lcC=> MYSyOlA1QTFyMh?=
AML-12  NFvNSoxHfW6ldHnvckBCe3OjeR?= MnvONlAh|ryP M1zOelMhcA>? NIHCNJB2eHKnZ4XsZZRmeyC2aHWgdIhwe3Cqb4L5cIF1cW:wIHzleoVteyCjdDDUbJIuPDFzIHHu[EBU\XJvNEmz NU\rNJlrOjZyNEi5PFU>
AML-12  MnS5SpVv[3Srb36gRZN{[Xl? NX;oSok4OjBizszN MVOxMVghcA>? NVTYNG9XcW6lcnXhd4V{KGeudXPvd4UheHKxZIXjeIlwdg>? M1\K[FI3ODR6OUi1
AML-12  M1HDZWZ2dmO2aX;uJGF{e2G7 MUeyNEDPxE1? M2X2eVMhcA>? NIDTbHF2eC2{ZXf1cIF1\XQEoGDnZ|FiNMLiUHXwZ4stKGGwZNMgS|Zx[8LibWLORUBt\X[nbIO= MkPWNlYxPDh7OEW=
AML-12  NXm3dYVSTnWwY4Tpc44hSXO|YYm= MoTYNlAh|ryP MoKyN{Bp NVf6U2xYcW6mdXPld{B1cGViZHXwbI9{eGixconsZZRqd25ib3[gR3JVSzMEoB?= Ml3jNlYxPDh7OEW=
RBMECs Mn3PSpVv[3Srb36gRZN{[Xl? MonTOeKh|ryP M1rOblEhcA>? M1jCdIlvcGmkaYTzJGVOSVBvSVmtbY5lfWOnZDDpcoFkfGm4YYTpc44hd2ZiUnHwNeKh NEfMZ4ozPjB2NE[2Ny=>
EndoC-βH1 NVXjRWRJTnWwY4Tpc44hSXO|YYm= Mlv3OeKh|ryP M{T1eVEhcA>? M4myVJBwfGWwdHnheIV{KGeudXPvd4UucW6mdXPl[EBqdnO3bHnuJJNm[3KndHnvckBqdiC2aHWgdJJme2WwY3Wgc4Yh\2y3Y3;z[S=> Mnz6NlYxOjh3NkK=
EndoC-βH1 NHjxUFlHfW6ldHnvckBCe3OjeR?= MW[1xsDPxE1? M3;DSVEhcA>? NIjQcWdt\WGmczD0c{BiKHO2cn;u[{BkSU2SIHnuZ5Jm[XOn NEi0O2MzPjB{OEW2Ni=>
SH-SY5Y NEiydHdHfW6ldHnvckBCe3OjeR?= MnSxN|Ah|ryP MkC5N|AhdWmw NVv3OVFoTE2VTx?= MkPrd4lodmmoaXPhcpRtgSCrbnPy[YF{\XNidHjlJIFkfGm4YYTpc44hd2ZiUFvB MWCyOlAzPTF|Nx?=
PC-3 MU\GeY5kfGmxbjDBd5NigQ>? NEnJUVQ1OCEEtV2= MoXjNkBp NHrlOXhFVVOR MoTXcIVi\HNidH:gVHAzSSCjY4TpeoF1cW:w MUCyOlAzOzh|Nh?=
PC-3 Ml\QR4VtdCCYaXHibYxqfHliQYPzZZk> NVKzeXNHPDBiwsXN MWWyOE81QC95MjDo MXLEUXNQ NHzKb2xl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgeIlu\SCmZYDlcoRmdnSueR?= MYqyOlAzOzh|Nh?=
SCG M4S4N2Z2dmO2aX;uJGF{e2G7 MWSyNEDPxE4EoB?= NHLkRWFFVVOR NE\UU|Jz\X[ncoPpZox6KHO3cIDy[ZN{\XNiSVvWJJdqfGhiYTDJR|UxKG:oIEK0MlQh|ryP MUCyOVk3OjF|Mh?=
HEK-293 MUDGeY5kfGmxbjDBd5NigQ>? MUGzOUDPxE4EoB?= MVnEUXNQ NXS4VmwzcW6mdXPld{BiKGOxboPwbYN2d3W|IPMAoIlv[WO2aY\heIlwduLCnTDv[kB1cGViS4[yMlEh[3W{cnXueC=> M4nvV|I2QTZ{MUOy
SCG MVrGeY5kfGmxbjDBd5NigQ>? MX:xNFAh|ryPwrC= MmX0SG1UVw>? M1u3NZJm\HWlZYOgeIhmKGW6Y3n0ZYJqdGm2eTDv[kBUS0dibnX1do9vew>? M{jnOFI2QTZ{MUOy
PCCL3 NVv1fXdZTnWwY4Tpc44hSXO|YYm= NHrrRlAyOCEEtV2= MYOyOEBp NXfuWYVT\W6qYX7j[ZMhTHWReEKgdJJwdW:2ZYKgeJJidnOlcnnweIlwdiCjY4Tpeol1gcLi4pEL M13MTlI2QTZyOUW2
3T3-L1 preadipocytes M{jJNWZ2dmO2aX;uJGF{e2G7 M4j0TlExKM7:TdMg MoXRNVIhcA>? MWfpcoR2[2W|IFPSSWIheGixc4Doc5J6dGG2aX;uJIFv\CCFL1XCVO6zKGW6cILld5Nqd25? M{nUdlI2QTJ6MEW4
H295R  NUD2PYFxTnWwY4Tpc44hSXO|YYm= NU[wPXZEOTEEoN88US=> NG\GZog1QMLiaB?= M{\kS4lv[3KnYYPld{B{fGW{b3nkJI1mfGGkb3zpeIV{KGmwIITo[UBidmS{b3flckwhdWmwZYLhcI8uKGGwZDDncJVkd2OxcoTpZ49q\CCyYYToe4F6ew>? MYqyOVg3QTV3Nh?=
PBMC MmTuSpVv[3Srb36gRZN{[Xl? MnvMOVDDqM7:TR?= M4jvXlI1yqCqwrC= M1vrVYlvcGmkaYTzJJRp\SCrbnPy[YF{\WRic3XjdoV1cW:wIH;mJHRPTiCrbnT1Z4VlKGK7IITo[UBFWEV? NU\Oc3h7OjV6Nk[wO|k>
GLUTag  M4mxWmZ2dmO2aX;uJGF{e2G7 NWHo[HdZOTEkgJpCuW0> M1jYeFAwOi92IHi= NG\5N2Z{fGmvdXzheIV{KEeOUD2xJJNm[3KndHnvckBkd3S{ZXH0[YQhf2m2aDDJRm1Z NGDZb5ozPTh|Mk[zNS=>
GLUTag  NGD3N|NHfW6ldHnvckBCe3OjeR?= NYf3TmkxOTEkgJpCuW0> Mn\BOEBp MnH1bY5kemWjc3XzJJRp\SCyQ2LFRkBt\X[nbIOge4l1cCC2aHWgTWJOYA>? NGLIVm4zPTh|Mk[zNS=>
BAECs M1r6e2Z2dmO2aX;uJGF{e2G7 M1WyRVI2KM7:TR?= NVfBZZBMOjRiaB?= Moe0[Y5p[W6lZYOgeIhmKGGldHn2ZZRqd25ib3[gVHBCWs7zIHL5JFUh|ryPIILld5ZmemG2cn;sMEBVPEiVLDDvdkA1NVCDUB?= Mm\4NlU4QTh6Mk[=
PC12 M33CSGZ2dmO2aX;uJGF{e2G7 Mn3nNlXDqM7:TR?= NULrXGRDPDhiaB?= M1S0SYFkfGm4YYTld{BkSU2S NV\3eGpbOjV5NkmzNFU>
GH3 NHT2e29HfW6ldHnvckBCe3OjeR?= NHPN[GIyyqEQvF2= MVm2MYg> M2LxUYF1fGWwdXH0[ZMhfGinIHPvdpJmdGG2aX;uJIJmfHenZX6gVHJNKGGwZDDCcYFtOSCneIDy[ZN{cW:w MmLtNlU4OjdyMUi=
GH3 MWXGeY5kfGmxbjDBd5NigQ>? NGW3b4oyyqEQvF2= MU[2MYg> M1\pSolv\HWlZYOgVHJNKGGwZDDCcYFtOSxiYoX0JI5wfCCFbH;jb{whdVKQQTDlfJBz\XO|aX;u Mon3NlU4OjdyMUi=
BeWo MV3GeY5kfGmxbjDBd5NigQ>? NHzQOlIyOOLCit88UeKh M4C0TlczKGh? NUnvZphKTE2VTx?= NYfJOpJxdWWmaXH0[ZMhSmWZbzDj[YxtKGSrZn\ldoVvfGmjdHnvci=> NGqzWWUzPTdzM{SyOS=>
oocytes MonySpVv[3Srb36gRZN{[Xl? MnXKOUDPxE1? M1rwdFI1KGh? NITJbIlifHSnboXheIV{KHKqLXnud5VtcW5iYXP0bY9vKG:wIH;vZ5l1\SCJVlLEJJNq\26rZnnjZY51dHoEoB?= MmHrNlU4ODd6NUS=
SC M2jIWGZ2dmO2aX;uJGF{e2G7 Mn\yNE42KM7:TR?= NY\UXFRjOjRiaB?= MmXHcYlucWOtczD0bIUh\W[oZXP0JI9nKGODTWCgZY5idG:pczDvckBQOSCjbnSgUWJRKGW6cILld5Nqd25? NWLSXYxmOjV5MEW4O|Q>
SC Mn72SpVv[3Srb36gRZN{[Xl? NW\zSnNOOC53IN88US=> NF3NUJI4OiCq NFTWd4ZqdmO{ZXHz[ZMh[m:2aDDLdo95NTJyIHHu[EBQOSCneIDy[ZN{cW:wIHnuJIF5d25vcnXsZZRm\CCVQ4OgZpV1KG:wbImgT5JwgC1{MNMg NUnZXGZVOjV5MEW4O|Q>
UACC-647  MVvGeY5kfGmxbjDBd5NigQ>? MVTEUXNQ NIDS[W1t\WGmczD0c{BiKHKrc3WgbY4h[0GPUDDs[ZZmdHNiKFXDOVDDqD4EoEKwMlM6yqEQvF2p Ml7uNlU4ODNyMkW=
UACC-647  MnzOSpVv[3Srb36gRZN{[Xl? NHW5OGQyOMLizszN MVWxOUBucW5? MWjEUXNQ MlrmbY5pcWKrdIOgSXJMKHCqb4PwbI9zgWyjdHnvci=> MnfKNlU4ODNyMkW=
UACC-647  MljqSpVv[3Srb36gRZN{[Xl? M2DZe|ExyqEQvF2= MUGxOUBucW5? MWnEUXNQ NEC0TYZqdmO{ZXHz[ZMh\UWIMjDwbI9{eGixconsZZRqd25ibHX2[Yx{yqB? MVKyOVcxOzB{NR?=
SH-SY5Y  M3PERmZ2dmO2aX;uJGF{e2G7 MWexNOKh|ryP NXyxV4V[OcLiaNMg NHPocJVqdmO{ZXHz[ZMhVFWFIHHjeIl3cXS7 NHHWOXYzPTV7N{SzNy=>
SH-SY5Y  Mm\PSpVv[3Srb36gRZN{[Xl? MXGxNOKh|ryP M4HXelHDqGkEoB?= NVvq[3RrcW6lcnXhd4V{KEGJQ{GgcXJPSSCuZY\lcC=> M3e2ZVI2PTl5NEOz
hADSCs NE\kTmxHfW6ldHnvckBCe3OjeR?= M4TlW|XjiIoEtV2= NIGxXHI{OCCvaX6= NXz4SVZwcW6lcnXhd4V{KGODTWCgcIV3\Wy| MUeyOVU6OTlyOB?=
HEK293  MkDKSpVv[3Srb36gRZN{[Xl? M1\VS|XjiIoEtV2= NFu0VYo{OCCvaX6= MWfpcoNz\WG|ZYOgZ2FOWCCuZY\lcJM> MUCyOVU6OTlyOB?=
3T3-L1 NETQco5HfW6ldHnvckBCe3OjeR?= NYfNS3Z6Oi53L{Wg{txO MXuyOEBpyqB? M1PPTZNq\26rZnnjZY51dHliZHXjdoVie2W|IFHUS2wheHKxdHXpckBmgHC{ZYPzbY9vKGG2IHHscEBld3OnczD0[ZN1\WR? MkOxNlU2QTB3OUe=
OCI-Ly1  NXjwd21ITnWwY4Tpc44hSXO|YYm= NVi3PFIxPDEEoN88US=> MXKxxsBpyqB? NX\BdZlLTE2VTx?= M4P2SYlv\HWlZYOgeIhmKGmwY4LlcYVvfCCxZjDjRW1RKGOxbnPlcpRz[XSrb37z NGfzTm4zPTV5NkKyNC=>
OCI-Ly18  M4HYeWZ2dmO2aX;uJGF{e2G7 NHnuVIg1OMLizszN MUSxxsBpyqB? MoTBSG1UVw>? MlnQbY5lfWOnczD0bIUhcW6lcnXt[Y51KG:oIHPBUXAh[2:wY3XueJJifGmxboO= M2Tx[FI2PTd4MkKw
BeWo NF65cJpHfW6ldHnvckBCe3OjeR?= M{fVPVIxyqEEtV2= MUO0POKhcA>? NFTOXnpFVVOR MmLMbY5kemWjc3XzJJRp\SCmaX\m[ZJmdnSrYYTpc44hd2ZiQnXXc{Bk\Wyucx?= M1rmS|I2PTZ4N{Sw
BeWo NHjjTJdHfW6ldHnvckBCe3OjeR?= NFjIU|YzOMLiwsXN NHfnXVI1QMLiaB?= M4qwb2ROW09? M4jqdIlv[3KnYYPld{B1cGViYXTo[ZNqd25ib3[gWGhRNTFibX;uc4N6fGW| NFL1W4YzPTV4Nke0NC=>
LNCaP  NFTKSI5HfW6ldHnvckBCe3OjeR?= NWK4b4hkOTEEoN88US=> MYOxNkBpyqB? M1PyW2ROW09? M3XlbIlv\HWlZYOgZUBlemGvYYTpZ{BqdmO{ZXHz[UBw\iCFUlXCNUBi[3Srdnn0fS=> MUKyOVU1QDB7OR?=
ThGCs  M3;l[GZ2dmO2aX;uJGF{e2G7 MmPYNVDjiIsQvF2= M3f5VlTjiIqq NWX5T4FL[XWpbXXueJMhUEmIMVGgcIV3\Wy|IIToZZQhf2W{ZTDzeIlufWyjdHXkJIJ6KEOxQ3yy NHfENWczPTR|M{CyOy=>
ThGCs  MUjGeY5kfGmxbjDBd5NigQ>? NYDXSYsyOTEkgJtOwG0> MXS05qCLcA>? NX\4TlgxcW6lcnXhd4V{KEOxQ3yyMYlv\HWlZXSgSWRPOsLiZ3Xu[UBmgHC{ZYPzbY9v NHXHb|YzPTR|M{CyOy=>
ThGCs  NVLNSIl5TnWwY4Tpc44hSXO|YYm= MmnyNVDjiIsQvF2= M4LpVlMhcA>? NYDuTHRMcW6qaXLpeJMhfGinIHXm[oVkfCCxZjDINm8zKG:wIFXEUlIhdVKQQR?= NWi1[WhWOjV2M{OwNlc>
RBMECs M13uWmZ2dmO2aX;uJGF{e2G7 MkjINE4xPS9yLkWvOUDPxE1? NVrZUFB5OC5{NTDo NIP4O|ZqdmO{ZXHz[ZMh[0GPUDDjc45k\W62cnH0bY9v M4\PdlI2PDF4NkWx
RBMECs M13xT2Z2dmO2aX;uJGF{e2G7 MWW1xsDPxE1? NXv4V2g2OSCq M17vOIJtd2OtczD0bIUh[WO2aY\heIlwdiCxZjDSbI9CN1KRQ1ugbY5lfWOnZDDifUBGVUGSLVnJ M3TEcFI2PDF4NkWx
RBMECs NXni[|Z[TnWwY4Tpc44hSXO|YYm= Ml3uOeKh|ryP M3n2cVEhcA>? M13Lc5Bz\X[nboTzJJRp\SCHTVHQMWlKNWmwZIXj[YQhXEWHUjD2ZYx2\SCmZXPy[YF{\Q>? MYSyOVQyPjZ3MR?=
RBMECs MY\GeY5kfGmxbjDBd5NigQ>? NWG3VopNPcLizszN M{j1R|EhcA>? M2fxdJBz\X[nboTzJJRp\SCrbnPy[YF{\SCrbjDIVnAh\my3eDDhZ5Jwe3NidHjlJGJVSiCrbnT1Z4VlKGK7IDDFUWFRNUmL M4frUFI2PDF4NkWx
RBMECs MlHTSpVv[3Srb36gRZN{[Xl? NYHGWYNUPcLizszN MmXsNUBp NX2zZplncW6qaXLpeJMhfGinIHTlZ5Jm[XOnZDDv[kBidW:3boSgc4YhYk9vMTDpckBOTnNiaX7keYNm\CCkeTDFUWFRNUmL NXHMS5FxOjV2MU[2OVE>
RBMECs M17oVGZ2dmO2aX;uJGF{e2G7 NE\5PXc2yqEQvF2= NEnmNnAyKGh? NFL2eJFz\X[ncoPld{B1cGViY3jhcodmeyCrbjDaU{0yKGSrc4TybYJ2fGmxbjDz[YVvKHerdHigSW1CWC2LSTD0doVifG2nboS= NEP6[lMzPTRzNk[1NS=>
RBMECs MnLlSpVv[3Srb36gRZN{[Xl? M175NlXDqM7:TR?= M3jWO|EhcA>? NVHKTnNI[myxY3vzJJRp\SCHTVHQMWlKNWmwZIXj[YQh[2ijbnflJIlvKE2OQzDwbI9{eGixconsZZRqd25? MoPJNlU1OTZ4NUG=
RBMECs MojtSpVv[3Srb36gRZN{[Xl? NVHITGxJPcLizszN NH\5UZcyKGh? MVzicI9kc3NidHjlJIFkfGmwIHP5eI9{c2WuZYTvckBz\WG{cnHu[4Vu\W62IIPl[Y4hf2m2aDDFUWFRNUmLIITy[YF1dWWwdNMg MUCyOVQyPjZ3MR?=
Primary bovine chondrocytes MkjaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU[1{txO NELVZow1QCCq M1PTRpJmfmW{c3XzJJRp\SCrbnjpZol1d3K7IHXm[oVkfCCxZjDj[Yxm[2:6aXKgc44heHKxbHnm[ZJifGmxbjDpckBoem:5dHigdIxifGViY3jvcoRzd2O7dHXz NXjhTHRIOjV2ME[wNVY>
EM1  MV\GeY5kfGmxbjDBd5NigQ>? M{DYPVE26oDMzszN MmOxOFghcA>? NF\KcoVz\WS3Y3XzJJRp\SCneIDy[ZN{cW:wIH;mxsBNUUcEoH;yxsBRXEeVMtMgbY7DqEODTGKtJI9zyqCHUFHDNk1{cWynbnPl[EBGVTFiY3XscJPDqA>? NXrhTo82OjV|N{i2OlE>
BeWo  Mn\QSpVv[3Srb36gRZN{[Xl? NHHxc5czOMLiwsXN NHvJd2I1QMLiaNMg MXLEUXNQyqB? NYf0OHgxcW6lcnXhd4V{KHSqZTDi[ZRiNWiFRzDy[Yxm[XOn NYe0epcyOjV|NkKyOlA>
BeWo  M3PSPWZ2dmO2aX;uJGF{e2G7 NEnEfYMzOMLiwsXN NGDSfG81QMLiaNMg MnGzSG1UV8Li NGLHd4hld3ewcnXneYxifGW|IITo[UBt\X[nbDDv[kBVVUWPRkG2 MkC5NlU{PjJ{NkC=
BeWo  MmXaSpVv[3Srb36gRZN{[Xl? M2P4TlIxyqEEtV2= NUnTfWZkPDkEoHlCpC=> MnnjSG1UV8Li NYrCcnd{\G:5boLl[5Vt[XSnczD0bIUhdGW4ZXygc4YhT0OPLUG= NVjnZlNDOjV|NkKyOlA>
granulosa cells M2C0WGZ2dmO2aX;uJGF{e2G7 MUWxNEDPxE1? MVmxNk8zPCCq MY\pcoNz\WG|ZYOgeIhmKGyndnXsd{Bw\sLiUlfTNuKhdVKQQR?= MXSyOVM{QTFyNR?=
granulosa cells M1X2NGZ2dmO2aX;uJGF{e2G7 NFjaPHUyOCEQvF2= MVexNk8zPCCq MnSybY5kemWjc3XzJJRp\SCuZY\lcJMhd2ZicnXwc5J1\XJiYXP0bZZqfHliZn;yJJRp\SCub37n[ZN1KG[{YXft[Y51KCkkiKK4OVQwMzF6UlfTNk5NXUNr Mo\0NlU{OzlzMEW=
granulosa cells NUTUbox3TnWwY4Tpc44hSXO|YYm= MoS5NVAh|ryP NHHLNokzPCCq M3jSbIlv[3KnYYPld{B1cGViaX70[Y5{cXS7IH;mJGRPSS:ycn;0[YlvKGOxbYDs[Zg> Mm\VNlU{OzlzMEW=
granulosa cells M4\ycGZ2dmO2aX;uJGF{e2G7 M3vHSVExKM7:TR?= M1vJTFI1KGh? NUfOTW9ScW6lcnXhd4V{KHSqZTDs[ZZmdHNib3[gVmdUOiCycn;tc5RmeiCjY4Tpeol1gQ>? M2\ucFI2OzN7MUC1
SK-N-AS  NVn5epRJS2WubDDWbYFjcWyrdImgRZN{[Xl? M4TH[lExKM7:TdMg NXjCUW5oOjRxNEigbC=> NWe3O5dZ\W6qYX7j[ZMhfGmvZT3k[ZBmdmSnboTsfUBk\WyudXzhdkB3cWGkaXzpeJnDqA>? MUSyOVI3PjB4Mx?=
SK-N-AS  Mm[wSpVv[3Srb36gRZN{[Xl? NYTpRpJ5OTBizszNxsA> M3XMcFI1KGh? Mo\YbY5kemWjc3XzJJRp\SClQV3QJIxmfmWuc9Mg NYXnSXBiOjV{Nk[wOlM>
SK-N-AS  NVPIU3JoTnWwY4Tpc44hSXO|YYm= MVixNEDPxE4EoB?= M1LqN|I1KGh? MluxbY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mJIN6[2yrbjDENS=> MUSyOVI3PjB4Mx?=
SK-N-AS  Mln0SpVv[3Srb36gRZN{[Xl? M2nsbVExKM7:TdMg NWLSfW1FOzBibXnu M1;0Tolv\HWlZYOgdIhwe3Cqb4L5cIF1cW:wIH;mJO6zNWOjdHXubY4hMHOnck[3OUktKHBvR2PLN:6zKCi|ZYK5LUBidmRiY3;uZ49ucXSjboSgbIlocGW{IHzleoVteyCxZjDhZ5RqfmVuIIXudIhwe3Cqb4L5cIF1\WRuIN8yMYNifGWwaX6= NHnkV2czPTJ4NkC2Ny=>
SK-N-AS  NH3YW4ZHfW6ldHnvckBCe3OjeR?= MV2xNEDPxE4EoB?= NH6yT48yOC9|MD:2NEBucW5? NUTWbHBIcW6lcnXhd4V{KGyndnXsd{Bw\iCyLd8yMYNifGWwaX6gLJNmejZ5NTmgZY5lKGmwZIXj[ZMh[WOldX31cIF1cW:wIH;mJJAu|rJvY3H0[Y5qdiBqc3XyOlc2MSCrbjCodIVzcSmwdXPs[YFzKHKnZ3nvcpM> M{nEUFI2OjZ4ME[z
SK-N-SH MVXD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MX:xNEDPxE4EoB?= NX3oVmZmPDhiaB?= NF\sVoJmdmijbnPld{BUUy2QLWPIJI5mfXKxYnzhd5RwdWFiY3XscEB3cWGkaXzpeJk> MonaNlUzPjZyNkO=
HEK‐CFTR M3;UbGZ2dmO2aX;uJGF{e2G7 MlXHNwKBmzVywrFOwG0> NYPzVGNsOC1zMjDtbY4> NEC5U4tFVVORwrC= Ml3nbY5lfWOnczDhJIRwe2YkgKDk[ZBmdmSnboSgbY9lcWSnIHXm[ox2gMLi NEPYdGYzPTJ4M{KwOy=>
L6 NULsWnlWTnWwY4Tpc44hSXO|YYm= NYLafWFJPDBiwsXN Mlj3NlQhcA>? MXLpcohq[mm2czDEUWgyNWmwZIXj[YQhSWu2IHHjeIl3[XSrb36= NH;UeIUzPTJ2N{W1NC=>
MIN6  MYjGeY5kfGmxbjDBd5NigQ>? MYKxNEDPxE4EoB?= M{DYblMhcA>? MWrpcoNz\WG|ZYOgSFMhdVKQQTDlfJBz\XO|aX;u M3LocFI2OjRzMUK0
ventricular cardiomyocytes  NFraTopHfW6ldHnvckBCe3OjeR?= NEL2ZpQxNjBzLUGwJO69VQ>? MoTXbY5kemWjc3XzJEBkSU2SIHHjZ5VufWyjdHnvci=> NWn6dG1POjV{MEOxNVM>
ventricular cardiomyocytes  MUPGeY5kfGmxbjDBd5NigQ>? MUKwMlAyNTFyIN88US=> M3PvRoV3d2unczDhckBqdm:2cn;wbYMhemW|cH;ud4UhOTJywsGxOUUh[WKxdnWgZoF{[Wxid3n0bEBidiCHQ{WwxsBw\iB{LkKgxtVO NV\sW4VYOjV{MEOxNVM>
BeWo  MoDlSpVv[3Srb36gRZN{[Xl? MWCyNEDDvU1? Mk\YOFghcA>? MW\EUXNQyqB? NUfNRol3cW6mdXPld{Bk\WyuIH\1d4lwdg>? Mmq3NlUyQDR2N{e=
THP-1  M3fSTGZ2dmO2aX;uJGF{e2G7 NHzMcVgyNzFyIN88US=> NGDLO|YzyqCq NF;KPIZFVVORwrC= NU\UWG9Ne3WycILld5NmeyCPQ2CtNUBxem:mdXP0bY9vyqB? MkPlNlUyPTR6OEK=
Huh-7 NW\xU|lkTnWwY4Tpc44hSXO|YYm= MXiwMVIxKM7:TR?= NGLz[mIzKGkEoB?= MUHy[ZN2dHS|IHnuJIEh\G:|ZT3k[ZBmdmSnboSgbY5kemWjc3WgbY4h[y2PeXOg[ZhxemW|c3nvckBifCC2aHWgdJJwfGWrbjDhcoQhdVKQQTDs[ZZmdHN? MWeyOVExQTh|NB?=
C6 NHziWo1HfW6ldHnvckBCe3OjeR?= MnK3NVAh|ryPwrC= M4\qZlIxKG2rbh?= NHOwcYxqdmO{ZXHz[ZMh[0GPUDDhZ4N2dXWuYYTpc44> NEfJU3czPTB4OUSxOy=>
SW480 M364UGZ2dmO2aX;uJGF{e2G7 NYrHSoJmPDEEoN88US=> M{HZbFQ5yqCq M3qycWROW09? MUnhZ5RqfmG2ZYOgVHAzSQ>? M1PtNFI1QTl5NEWx
HT-29  M1HNVGZ2dmO2aX;uJGF{e2G7 NEfh[201OMLizszN NYDGbFNRPDkEoHi= M4[wdWROW09? NInUXodi[3SrdnH0[ZMhWFB{QR?= MWeyOFk6PzR3MR?=
SW480 NH7xUlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWC0NOKh|ryP MV2wMVczKGh? NUizZYZETE2VTx?= MX;pcohq[mm2czDj[YxtKGe{b4f0bEB1cW2nIHTldIVv\GWwdHz5 MVeyOFk6PzR3MR?=
HT-29  MnzwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVS0NOKh|ryP M4rLT|AuPzJiaB?= MWrEUXNQ MmO1bY5pcWKrdIOgZ4VtdCCpcn;3eIghfGmvZTDk[ZBmdmSnboTsfS=> M{nidVI1QTl5NEWx
SW480 MX;GeY5kfGmxbjDBd5NigQ>? NYT6XpB{PDEEoN88US=> NIP3eog4KGR? M{W0fmROW09? NY[4OZl{emWmdXPld{Bkd2yxbn;zdIhmemViZn;ycYF1cW:wIHPhdIFjcWyrdIpCpC=> NWfLO|E1OjR7OUe0OVE>
HT-29  M33ufGZ2dmO2aX;uJGF{e2G7 NHrrUFg1OMLizszN MV[3JIQ> NFPoPGRFVVOR MXXy[YR2[2W|IHPvcI9vd3OyaHXy[UBnd3KvYYTpc44h[2GyYXLpcIl1gcLi M2q0R|I1QTl5NEWx
SW480 MVfBdI9xfG:|aYOgRZN{[Xl? MVO0NOKh|ryP MlrxOFjDqGh? MmHnSG1UVw>? NHrKbW1qdmS3Y3XzJIFvKGGldHn2ZZRqd25ib3[gZ4F{eGG|ZTCzM|c> NX[0dnJkOjR7OUe0OVE>
HT-29  MmTlRZBweHSxc3nzJGF{e2G7 MnXMOFDDqM7:TR?= NFLCfnU1QMLiaB?= MX;EUXNQ MYrpcoR2[2W|IHHuJIFkfGm4YYTpc44hd2ZiY3HzdIF{\SB|L{e= M4O5VVI1QTl5NEWx
SW480 M2\vdmFxd3C2b4Ppd{BCe3OjeR?= M4DxS|QxyqEQvF2= MWe0POKhcA>? NGHMNW5FVVOR NX3td3RJcW6mdXPld{BkcGGwZ3XzJIlvKHSqZTDwbI9{eGixconsZZRqd25ic4TheJV{KG:oIGDQNmEhfGG{Z3X0dy=> M{\BT|I1QTl5NEWx
HT-29  M1;FNmFxd3C2b4Ppd{BCe3OjeR?= M3HIcFQxyqEQvF2= M4rCVVQ5yqCq NFjBdG9FVVOR MkXtbY5lfWOnczDjbIFv\2W|IHnuJJRp\SCyaH;zdIhwenmuYYTpc44he3SjdIXzJI9nKFCSMlGgeIFz\2W2cx?= NUL0OoVNOjR7OUe0OVE>

多くの細胞株試験データを見る場合、クリックしてください

お薦めの試験操作(参考用のみ)

溶解度 (25°C)

体外 DMSO 82 mg/mL (199.75 mM)
Ethanol 37 mg/mL (90.13 mM)
Water Insoluble

* 溶解度検測はSelleck技術部門によって行いますので、文献より提供された溶解度と差異がある可能性がありますが、生産工芸と不同ロット(lot)で起きる正常な現象ですから、ご安心ください。

化学情報

分子量 410.5
化学式

C22H34O7

CAS No. 66575-29-9
保管
別名 Coleonol

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01254006 Completed Glaucoma University of Roma La Sapienza|vingolo enzo maria|domanico daniela|salvatore serena null --

技術サポート

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

Handling Instructions

他の質問がある場合は、お気軽くお問合せください。

  • * 必須

cAMPシグナル伝達経路

Tags: Forskolinを買う | Forskolin ic50 | Forskolin供給者 | Forskolinを購入する | Forskolin費用 | Forskolin生産者 | オーダーForskolin | Forskolin化学構造 | Forskolin分子量 | Forskolin代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID